TP53 and acute myeloid leukemia: MDS stem cells acquire early initiating mutations (such as in TET2, U2AF1, and TP53) then accumulate additional mutations (such as in NOTCH2 and KMT2C), resulting in subclones that can develop into both MDS blasts and pre-AML/AML stem cells.